CLAIMS

1. Use of an anti-Adrenomedullin (ADM) antibody, anti-ADM antibody fragment binding to adrenomedullin or anti-ADM non-Ig protein scaffold binding to adrenomedullin in the manufacture of a medicament for regulating fluid balance in a patient in need thereof by treating an acute disease or acute condition of the patient that suffers from fluid imbalance, wherein said antibody, antibody fragment or non-Ig scaffold binds to a region of at least 4 amino acids within the sequence of amino acids 1-21 of mature human ADM:

YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 23).

2. The use of claim 1, wherein the acute disease or condition is edema.

3. The use of claim 1 or 2, wherein said antibody, antibody fragment or non-Ig scaffold is monospecific.

4. The use of any one of claims 1 to 3, wherein said antibody, antibody fragment or non-Ig scaffold exhibits a binding affinity to ADM of at least 10^{-7} M.

5. The use of any one of claims 1 to 4, wherein said antibody, antibody fragment or non-Ig scaffold is not ADM-binding-Protein-1 (complement factor H).

6. The use of any one of claims 1 to 5, wherein said antibody, antibody fragment or non-Ig scaffold recognizes and binds to an epitope comprising the N-terminal end amino acid of mature human ADM and wherein said antibody, antibody fragment or non-IG scaffold does not bind N-terminal extended, N-terminal modified Adrenomedullin or N-terminal degraded adrenomedullin.

7. The use of any one of claims 1 to 6, wherein said antibody, antibody fragment or non-Ig scaffold is an ADM stabilizing antibody, antibody fragment or non-Ig scaffold that

enhances the half life ($t_{1/2}$ half retention time) of adrenomedullin in serum, blood or plasma by at least 10 %, at least 50 %, greater than 50 %, or greater than 100 %.

8. The use of any one of claims 1 to 7, wherein said antibody, antibody fragment or non-Ig scaffold blocks the circulating ADM bioactivity not more than 80 %, or not more than 50%, wherein the bioactivity of ADM is determined in a human recombinant Adrenomedullin receptor cAMP functional assay.

9. The use of any one of claims 1 to 8, wherein the patient suffers from one or more of SIRS, sepsis, diabetes, cancer, heart failure, shock or kidney dysfunction.

10. The use of any one of claims 1 to 9, wherein said antibody, or antibody fragment is an antibody or antibody fragment that binds to ADM or a fragment thereof that binds to ADM, wherein the heavy chain of said antibody or antibody fragment comprises the sequences

SEQ ID NO: 1
GYTFSRYW

SEQ ID NO: 2
ILPGSGST

SEQ ID NO: 3
TEGYEYDGFDY

and wherein the light chain comprises the sequences
SEQ ID NO:4
QSIVYSNGNTY

SEQ ID NO: 5
RVS

SEQ ID NO: 6
FQGSHIPYT.

11. The use of claim 10, wherein said antibody or antibody fragment comprises at least one of the sequences:

SEQ ID NO: 7 (AM-VH-C)
QVQLQQSGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEIL
PGSGSTNYNEKFKGKATITADTSSNTAYMQLSSLTSEDSAVYYCTEGYEYDGF
DYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
VDKRVEPKHHHHHH

SEQ ID NO: 8 (AM-VHJ)
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWISWVRQAPGQGLEWMGRI
LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDG
FDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKHHHHHH

SEQ ID NO: 9 (AM-VH2-E40)
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWMGRI
LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDG
FDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVIPSSSLGTQTYICNVNHKPSNTKV
DKRV EPKHHHHHH

SEQ ID NO: 10 (AM-VH3-T26-E55)
QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWISWVRQAPGQGLEWMGEI
LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDG
FDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKHHHHHH

SEQ ID NO: 11 (AM-VH4-T26-E40-E55)

QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWIEWVRQAPGQGLEWMGEI
LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDG
FDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKHHHHHH

SEQ ID NO: 12 (AM-VL-C)
DVLLSQTPLSLPVSLGDQATISCRSSQSIVYSNGNTYLEWYLQKPGQSPKLLIY
RVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHIPYTFGGGTK
LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
NRGEC

SEQ ID NO: 13 (AM-VL1)
DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLNWFQQRPGQSPRRLIY
RVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGQGT
KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
FNRGEC
or
SEQ ID NO: 14 (AM-VL2-E40)
DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWFQQRPGQSPRRLIY
RVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGQGT
KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
FNRGEC

12. The use of any one of claims 1 to 11, wherein said antibody, antibody fragment or non-Ig scaffold is a modulating antibody, modulating antibody fragment or modulating non-Ig scaffold that enhances the half life ($t_{1/2}$ half retention time) of adrenomedullin in serum, blood or plasma by at least 10 %, at least 50 %, greater than 50 %, or greater than 100% and that blocks the bioactivity of ADM not more than 80 %, or not more than 50%, wherein the bioactivity of ADM is determined in a human recombinant Adrenomedullin receptor cAMP functional assay.

13. The use of any one of claims 1 to 12, wherein said antibody, antibody fragment or non-Ig scaffold does not bind to the C-terminal portion of ADM, amino acids 43-52 of ADM

PRSKISPQGY-NH2
(SEQ ID NO:25).

14. The use of any one of claims 1 to 13, wherein the medicament is to be administered with catecholamine and/or one or more fluids, wherein the catecholamine and/or fluids are to be administered intravenously.

15. The use of any one of claims 1 to 14, wherein the medicament is to be administered with ADM binding protein and/or one or more further active ingredient.

16. The use of any one of claims 1 to 15, wherein the medicament is not for primary treatment of said acute disease or acute condition.

17. The use of any one of claims 1 to 16, wherein said medicament is formulated as a solution or in a freeze-dried state.

18. The use of claim 17, wherein the solution is a ready-to-use solution.

19. The use of any one of claims 1 to 18, wherein said medicament is for regulating the systemic fluid balance in the patient.